Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trialDiamant Thaçi, Marius Ardeleanu, Eric L. Simpson et al.|The Lancet|2015Cited by 566
Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trialsEmma Guttman‐Yassky, Alan D. Irvine, Diamant Thaçi et al.|The Lancet|2021Cited by 538
OP0220 Randomized, double-blind, global clinical trial to evaluate equivalence of CHS-1420 to adalimumab in patients with psoriasis and psoriatic arthritisJames R. O’Dell, Barbara Finck, Alan Kivitz et al.|Annals of the Rheumatic Diseases|2017Cited by 3